Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02618187 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis
A Phase 1 study, sponsored by Seres Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT02618187 is a Phase 1 study that has completed, run by Seres Therapeutics. The registered enrollment target is 58 participants.
The verdict
NCT02618187, a Phase 1 study, has completed, sponsored by Seres Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
A Multiple Dose Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects with Mild-to-Moderate Ulcerative Colitis.
Interventions
- DRUG Placebo
- DRUG SER-287
- DRUG Placebo Pre-Treat
- DRUG Vancomycin Pre-Treat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2016-01-13 |
| Est. Completion | 2018-01-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02618187
The ClinicalTrials.gov registry entry for NCT02618187 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seres Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02618187 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02618187 about?
NCT02618187 is a clinical study titled "A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis". A Multiple Dose Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects with Mild-to-Moderate Ulcerative Colitis.
What is the current status of trial NCT02618187?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2016-01-13. Estimated completion is 2018-01-26.
What interventions are being tested in trial NCT02618187?
The interventions under investigation include: Placebo (DRUG), SER-287 (DRUG), Placebo Pre-Treat (DRUG), Vancomycin Pre-Treat (DRUG).
Who is sponsoring clinical trial NCT02618187?
This trial is sponsored by Seres Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.